BOSTON--(

波士顿--(

BUSINESS WIRE

商业热线

)--

)--

Nimbus Therapeutics

Nimbus疗法

, LLC ('Nimbus Therapeutics' or 'Nimbus'), a biotechnology company that designs and develops breakthrough medicines for patients through its powerful computational drug discovery engine, today announced the advancement of its clinical oncology therapeutic pipeline, and the appointment of Peter J. Tummino, Ph.D., to President of Research and Development.

，LLC（“Nimbus Therapeutics”或“Nimbus”）是一家通过其强大的计算药物发现引擎为患者设计和开发突破性药物的生物技术公司，今天宣布推进其临床肿瘤治疗管道，并任命Peter J.Tummino博士为研发总裁。

Dr. Tummino will be responsible for advancing the company’s product portfolio through all phases of discovery and clinical development..

Tummino博士将负责在发现和临床开发的所有阶段推进公司的产品组合。。

The company announced the completion of an investigational new drug (IND) application submission for NDI-219216, a novel Werner syndrome helicase (WRN) inhibitor in development for the treatment of microsatellite instability high (MSI-H) tumors. Nimbus plans to initiate the first clinical trial of NDI-219216 in the first half of 2025 under the leadership of Anita Scheuber, M.D., Ph.D., Senior Vice President, Therapeutic Area Head, Oncology..

该公司宣布完成NDI-219216的研究性新药（IND）申请提交，NDI-219216是一种正在开发的新型Werner综合征解旋酶（WRN）抑制剂，用于治疗微卫星不稳定性高（MSI-H）肿瘤。Nimbus计划在2025年上半年启动NDI-219216的首次临床试验，由医学博士、博士、高级副总裁、肿瘤学治疗领域负责人Anita Scheuber领导。。

'We are encouraged by the building momentum in our oncology portfolio including important advances in our non-covalent WRN inhibitor program, with data indicating NDI-219216 has the potential to be a best-in-class agent,' said Dr. Tummino.

Tummino博士说：“我们对肿瘤学投资组合的发展势头感到鼓舞，包括我们非共价WRN抑制剂项目的重要进展，数据表明NDI-219216有可能成为一流的药物。”。

'NDI-219216 has demonstrated compelling preclinical data, including significant tumor regression and complete responses at low oral doses across tumor types. The preclinical safety studies suggest a promising benefit-risk profile as we prepare to evaluate this compound in patients. We are excited to advance NDI-219216 into a first-in-human clinical trial later this year,' said Dr.

NDI-219216已经证明了令人信服的临床前数据，包括显着的肿瘤消退和低剂量口服肿瘤类型的完全反应。临床前安全性研究表明，当我们准备在患者中评估该化合物时，有希望的益处-风险概况。我们很高兴在今年晚些时候将NDI-219216推进首次人体临床试验。

Scheuber..

舍伯。。

The company recently completed its Phase 1/2 clinical study of NDI-101150, a highly selective and potent hematopoietic progenitor kinase 1 (HPK1) inhibitor, for the treatment of advanced solid tumors. Clinical data presented in November 2024 at the Society for Immunotherapy of Cancer (SITC) 39

该公司最近完成了NDI-101150（一种高选择性和有效的造血祖细胞激酶1（HPK1）抑制剂）的1/2期临床研究，用于治疗晚期实体瘤。2024年11月在癌症免疫治疗学会（SITC）39上提交的临床数据

th

第

Annual Meeting demonstrated monotherapy efficacy with a favorable safety profile that supports potential combination therapy approaches. The company is actively evaluating opportunities to maximize the therapeutic potential of this program.

年会证明了单一疗法的疗效，具有良好的安全性，支持潜在的联合治疗方法。该公司正在积极评估机会，以最大限度地发挥该计划的治疗潜力。

Nimbus continues to progress drug discovery efforts across metabolic and autoimmune targets as well, including the development of novel therapies that activate AMP-activated protein kinase (AMPK) to treat metabolic disorders as part of an ongoing research collaboration and exclusive worldwide license agreement with Eli Lilly and Company.

Nimbus还在代谢和自身免疫靶标方面继续推进药物发现工作，包括开发激活AMP活化蛋白激酶（AMPK）治疗代谢紊乱的新型疗法，作为与礼来公司正在进行的研究合作和独家全球许可协议的一部分。

Nimbus has also expanded its pipeline with the addition of new undisclosed therapeutic targets leveraging its novel computational and structure-based drug design approach..

Nimbus还利用其新颖的计算和基于结构的药物设计方法，增加了新的未公开的治疗靶点，从而扩大了其管道。。

'Nimbus made significant progress in 2024 in our discovery and development programs across oncology, immunology, and metabolism, bringing us one step closer to our ultimate goal of delivering transformative medicines to patients,' said Jeb Keiper, M.S., M.B.A., Chief Executive Officer of Nimbus. 'Peter’s appointment to President of R&D reflects his exceptional leadership and deep expertise in drug discovery and development, and his expanded role will be instrumental in advancing our innovative pipeline.

Nimbus首席执行官杰布·凯珀（Jeb Keiper，M.S.，M.B.A.）说：“2024年，Nimbus在肿瘤学、免疫学和新陈代谢领域的发现和开发项目取得了重大进展，使我们离向患者提供变革性药物的最终目标又近了一步。”彼得被任命为研发总裁反映了他在药物发现和开发方面的卓越领导才能和深厚的专业知识，他扩大的角色将有助于推进我们的创新渠道。

We continue to broaden our drug discovery engine to unlock new difficult-to-drug targets with compelling biology through deep computational expertise, a breadth of internal drug discovery expertise, and key partnerships. We look forward to multiple key milestones in the coming year.'.

我们继续扩大我们的药物发现引擎，通过深入的计算专业知识，广泛的内部药物发现专业知识和关键合作伙伴关系，以引人注目的生物学来解锁新的难以药物靶标。我们期待着来年取得多个关键里程碑。”。

Mr. Keiper will provide an overview of the company’s progress, pipeline, and anticipated milestones for 2025 and beyond at the 43

凯珀先生将在第43届会议上概述公司的进展、管道以及2025年及以后的预期里程碑

rd

rd公司

Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 7:30 a.m. PT.

2025年1月13日星期一上午7:30，摩根大通医疗保健年度会议。

About Nimbus Therapeutics

Nimbus Therapeutics is a clinical-stage, structure-based drug discovery company developing novel small molecule medicines designed to act against well-validated but difficult-to-drug targets implicated in multiple human diseases. The company advances promising research based on a unique strategy that combines leading-edge computational technologies with a tailored array of machine learning-based predictive modeling approaches.

Nimbus Therapeutics是一家临床阶段，基于结构的药物发现公司，开发新型小分子药物，旨在对抗多种人类疾病中经过充分验证但难以药物靶点。该公司基于独特的策略推进了有前景的研究，该策略将前沿计算技术与定制的基于机器学习的预测建模方法相结合。

Nimbus' pipeline includes NDI-219216, a Werner syndrome helicase (WRN) inhibitor in development for microsatellite instability high (MSI-H) tumors, as well as a diverse portfolio of preclinical programs focused on cancer, autoimmune conditions, and metabolic diseases. The company is headquartered in Boston, Mass.

Nimbus的管道包括NDI-219216，一种Werner综合征解旋酶（WRN）抑制剂，正在开发用于微卫星不稳定性高（MSI-H）肿瘤，以及针对癌症，自身免疫性疾病和代谢性疾病的多种临床前计划。该公司总部位于马萨诸塞州波士顿。

To learn more about Nimbus, please visit .

要了解有关Nimbus的更多信息，请访问。

www.nimbustx.com

www.nimbustx.com

.

.